Phyto Partners

The firm's website directs all external inquiries to Larry Schnurmacher, suggesting he is the central decision-maker. No other investment committee members, partners, or principals are listed publicly. This concentration of contact implies a founder-led, lean deal team structure.

Phyto Psyche applies the same venture framework — early-stage entry into a stigmatized, soon-to-be-regulated sector — to neurowellness and brain health. The parent firm sees this as structurally analogous to its 2015 cannabis entry, targeting companies before institutional capital arrives. Both funds focus on ancillary and service-layer businesses rather than direct cultivation or drug development.

Phyto's stated preference is for high-margin products and services sold to licensed operators, not the operators themselves. Its cannabis portfolio includes ancillary picks like Marijuana Doctor and Agrify. This approach reduces direct federal regulatory exposure while capturing industry growth.

The firm lists co-investment among its strategies, indicating it both leads and participates alongside other venture investors. Specific co-investors are not publicly named. The contact page invites accredited investors to learn about the Phyto investment opportunity, suggesting outside LP participation is available.

The firm credits its early cannabis success to connecting with the right people and providing venture capital to early industry operators, a phrase lifted from its website. It is publicly extending that network-based sourcing model into psychedelics. No proprietary sourcing channel is described beyond founder relationships and industry participant connectivity.